Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp158 | Cancer and bone: basic, translational and clinical | ECTS2013

Role of receptor activity modifying proteins in skeletal regulation

Pacharne Suruchi , Richards Gareth , Wang Ning , Skerry Timothy , Caron Kathleen

Receptor activity modifying proteins (RAMPs 1, 2 and 3) are a class of important accessory proteins that interact and regulate several G-protein coupled receptor (GPCR) activity by finely modulating ligand interaction and in some cases trafficking receptors to cell surface.Predominant roles of RAMPs include ligand selectivity in receptors for Calcitonin (CT) family of peptides that comprise calcitonin, calcitonin gene related peptide, amylin and Adrenome...

ba0002p185 | (1) | ICCBH2013

An unusual presentation of progressive osseous heteroplasia in a 7-year-old female child

Schrander D E , Welting T J , Schrander J J P , van Rhijn L W , Korver-Keularts I , Schrander-Stumpel C T R M

Background: Progressive osseous heteroplasia (POH) (OMIM 166350) is a rare autosomal dominant condition, characterized by heterotopic ossification of the skin, subcutaneous fat and deep connective tissue. This condition is distinct from Albright’s hereditary osteodystrophy or Mccune–Albright syndrome (AHO) (OMIM 103580) and fibrodysplasia ossificans progressiva (FOP) (OMIM 135100).Presenting problem: We present an unu...

ba0001pp450 | Osteoporosis: treatment | ECTS2013

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

Hattersley Gary , Hansen Kris , Determan Amy , Brown Ken , Mckay Kate , Guerriero Jonathan , McCarthy Dan , Lyttle C Richard , St L O'Dea Louis

BA058 is being developed as an anabolic therapy for the treatment of osteoporosis. Daily BA058 SC injection has produced promising safety and efficacy results in early clinical studies, and is currently enrolling in a Phase 3 fracture prevention study. There is, however, a significant need for an alternative to injection that improves patient convenience and compliance. We have investigated the use of a solid Microstructured Transdermal System (3M) for transdermal (TD) deliver...

ba0003pp14 | Arthritis and other joint diseases: translational and clinical | ECTS2014

Effect of risedronate on painful periprosthetic resorption of total hip arthroplasty: preliminary observational study

Behra-Marsac Aurelie , Bonnet Christine , Mabit Christian , Coste Cedric , Preux Pierre-Marie , Vergne-Salle Pascale , Dufauret-Lombard Carine , Treves Richard , Bertin Philippe

Total hip arthroplasty (THA) is the treatment for severe hip osteoarthritis. It improves the quality of life, pain and patient autonomy. However, a periprosthetic resorption may occur, in 3–5% of patients after 10 years of the primary surgery requiring implant replacement. Bisphosphonates (BP), inhibitors of bone resorption, represent a potential candidate for modulating periprosthetic bone loss. Randomized controlled trials have also suggested that BP could prevent early...

ba0003pp360 | Osteoporosis: treatment | ECTS2014

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

Hawley Sam , Wallace Gemma , Javaid M Kassim , Rubin Katrine , Judge Andrew , Vestergaard Peter , Eastell Richard , Diez-Perez Adolfo , Arden Nigel K , Cooper Cyrus , Prieto-Alhambra Daniel , Abrahamsen Bo

Objective: To identify predictors of inadequate response to oral bisphosphonate therapy, defined as the incidence of ≧2 fractures while on treatment among incident oral bisphosphonate users with high refill compliance (≧80%).Material and methods: Data from computerized records and pharmacy invoices were obtained from SIDIAP (Catalonia, E) and Danish Health Registries (DK) for all incident users of oral bisphosphonates in 2006–2007 and 2000&#15...

ba0005p76 | Bone development/growth and fracture repair | ECTS2016

Multicentre study reveals poor correlation between in vitro and in vivo assessments of biomaterials for bone-regeneration

Billstrom Gry Hulsart , Dawson Jon , Hofmann Sandra , Muller Ralph , Stoddart Martin , Alini Mauro , Redl Heinz , Haj Alicia El , Brown Robert , Salih Vehid , Hilborn Jons , Larsson Sune , Oreffo Richard

Introduction: Research on biomaterials for bone regeneration generates a plethora of new biomaterials requiring evaluation with reliable and comparable methods of biocompatibility and functionality for clinical translation. To reduce the burden of in vivo assessment, there is a need for refined in vitro assays that are predictive of in vivo outcomes. This retrospective study correlated in vitro results with in vivo outcomes observed...

ba0006p138 | (1) | ICCBH2017

Fibrodysplasia ossificans progressiva: baseline characteristics of 101 subjects participating in a global, longitudinal, natural history study

Kaplan Frederick S , Hsiao Edward C , Baujat Genevieve , Brown Matthew A , De Cunto Carmen , Di Rocco Maja , Keen Richard , Al Makkadam Mona , Grogan Donna R , Pignolo Robert J

Objectives: Progressive heterotopic ossification in fibrodysplasia ossificans progressiva (FOP; OMIM #135100) begins in childhood and leads to irreversible restriction of movement, functional impairment, and shortened life-span. Baseline data from an on-going, global, 3-year, natural history study (NHS) describe FOP disease characteristics, and retrospective flare-up history, causes/symptoms, and outcomes.Methods: Data from 101 subjects (recruited from 2...

ba0007oc27 | (1) | ICCBH2019

Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)

Kaplan Frederick , Hsiao Edward C , Baujat Genevieve , Keen Richard , De Cunto Carmen , Di Rocco Maja , Brown Matthew A , Al Mukaddam Mona M , Grogan Donna R , Pignolo Robert J

Objective: FOP is a rare, severely disabling disease characterized by episodic flare-ups and accumulation of heterotopic ossification (HO) leading to restricted movement, physical disability, and early death. Data from two Phase 2 interventional studies and one natural history study (NHS) were used to evaluate whether palovarotene could reduce HO following an FOP flare-up.Methods: HO volume at the flare-up site was determined by CT at baseline and 12 wee...

ba0007p9 | (1) | ICCBH2019

Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study

Duckham Rachel L , Hyde Natalie K , Brennan-Olsen Sharon L , Hesketh Kylie , Teo Wei-Peng , Rodda Christine , Walsh Adam , Laing Emma M , Lewis Richard D

Objective: Autism Spectrum Disorder (ASD) is associated with lower bone mass in children. Physical activity and nutrition influence bone pathophysiology, and differences in these lifestyle factors are observed between children with vs. without ASD; however, whether these factors contribute to bone differences is unknown. We examined if: 1) differences existed in bone mineral density (BMD), content (BMC), or bone geometry in boys with vs without ASD and 2) whether physical acti...